{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:13:42Z","timestamp":1769584422372,"version":"3.49.0"},"reference-count":27,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"crossref","award":["423641\/2021-2"],"award-info":[{"award-number":["423641\/2021-2"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,6,3]]},"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is an incurable malignant neoplasm that accounts for approximately 1% of all cancers and 10% of haematological malignancies. Bortezomib is one of the most commonly used medications in first-line treatment and subsequent relapses, either as a single agent or in combination with other therapies. This study aims to assess the effects of bortezomib on the overall survival (OS), progression-free survival, overall response rate, time to next treatment, health-related quality of life, compliance, adverse events and treatment-related death in patients with MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We have performed a systematic review and meta-analysis and will include both randomised and non-randomised controlled studies where the effect of bortezomib was compared in similar or dissimilar background therapies in each arm. General and adaptive search strategies have been created for the following electronic health databases: Embase, Medline, LILACS and CENTRAL. Two reviewers have independently selected eligible studies, will assess the risk of bias, and will extract data from the included studies. Similar outcomes will be plotted in the meta-analysis using the Stata Statistical Software V.17. The relative risk will be calculated with a 95% CI as the effect size of bortezomib. For the OS and progression-free survival, we calculate the overall OR from the HRs of each included study. Peto\u2019s one-step OR will be calculated for event rates below 1%. We will use the Grading of Recommendations Assessment, Development and Evaluation system to evaluate the certainty of evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>As no primary data collection will be undertaken, formal ethical assessment is not required. We plan to present the results of this systematic review in a peer-reviewed scientific journal, conferences and popular press.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42020151142.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-061808","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:01:57Z","timestamp":1656460917000},"page":"e061808","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of bortezomib on the treatment of multiple myeloma: a systematic review protocol"],"prefix":"10.1136","volume":"12","author":[{"given":"Lucas Oliveira","family":"Cantadori","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Universidade Estadual Paulista J\u00falio de Mesquita Filho C\u00e2mpus de Botucatu Faculdade de Medicina, Botucatu, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9480-4995","authenticated-orcid":false,"given":"Rafael Dezen","family":"Gaiolla","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Universidade Estadual Paulista J\u00falio de Mesquita Filho C\u00e2mpus de Botucatu Faculdade de Medicina, Botucatu, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9316-4167","authenticated-orcid":false,"given":"Vania dos Santos","family":"Nunes-Nogueira","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Universidade Estadual Paulista J\u00falio de Mesquita Filho C\u00e2mpus de Botucatu Faculdade de Medicina, Botucatu, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"key":"2025121408532386000_12.6.e061808.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"key":"2025121408532386000_12.6.e061808.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"2025121408532386000_12.6.e061808.3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2025121408532386000_12.6.e061808.4","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"2025121408532386000_12.6.e061808.5","first-page":"10","article-title":"Relapsed or relapsed\/refractory multiple myeloma","volume":"4","author":"Kurtin","year":"2013","journal-title":"J Adv Pract Oncol"},{"key":"2025121408532386000_12.6.e061808.6","first-page":"981","article-title":"Multiple myeloma: 2018 update on diagnosis, risk\u2010stratification, and management","volume":"93","year":"2018","journal-title":"Am J Hematol"},{"key":"2025121408532386000_12.6.e061808.7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"2025121408532386000_12.6.e061808.8","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"2025121408532386000_12.6.e061808.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-104984"},{"key":"2025121408532386000_12.6.e061808.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"2025121408532386000_12.6.e061808.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"2025121408532386000_12.6.e061808.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015909"},{"key":"2025121408532386000_12.6.e061808.13","unstructured":"Md S . Bortezomibe para O tratamento de pacientes adultos CoM mieloma m\u00faltiplo previamente tratados. Conitec, 2020: 28."},{"key":"2025121408532386000_12.6.e061808.14","unstructured":"Md S . Bortezomibe para O tratamento de pacientes adultos CoM mieloma m\u00faltiplo, n\u00e3o previamente tratados, eleg\u00edveis AO transplante aut\u00f3logo de c\u00e9lulastronco hematopoi\u00e9ticas. Conitec, 2020: 29."},{"key":"2025121408532386000_12.6.e061808.15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00277-015-2522-9","article-title":"Changes in survival rate of multiple myeloma after the introduction of bortezomib: a single institutional experience over 20 years","volume":"95","author":"Fujisawa","year":"2016","journal-title":"Ann Hematol"},{"key":"2025121408532386000_12.6.e061808.16","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00277-019-03602-4","article-title":"Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries","volume":"98","author":"Hungria","year":"2019","journal-title":"Ann Hematol"},{"key":"2025121408532386000_12.6.e061808.17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bjh.16124","article-title":"Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (holA) observational study, 2008-2016","volume":"188","author":"de Moraes Hungria","year":"2020","journal-title":"Br J Haematol"},{"key":"2025121408532386000_12.6.e061808.18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208920","article-title":"Clinical outcomes of bortezomib-based therapy in myeloma","volume":"13","author":"Djebbari","year":"2018","journal-title":"PLoS One"},{"key":"2025121408532386000_12.6.e061808.19","first-page":"CD010816","article-title":"Bortezomib for the treatment of multiple myeloma","volume":"4","author":"Scott","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121408532386000_12.6.e061808.20","doi-asserted-by":"crossref","unstructured":"Tufanaru CMZ , Aromataris E , Campbell J . Chapter 3: Systematic reviews of effectiveness. In: Aromataris E , Munn Z , eds. JBI manual for evidence synthesis. JBI, 2020.","DOI":"10.46658\/JBIRM-17-03"},{"key":"2025121408532386000_12.6.e061808.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647"},{"key":"2025121408532386000_12.6.e061808.22","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"2025121408532386000_12.6.e061808.23","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00136"},{"key":"2025121408532386000_12.6.e061808.24","unstructured":"Higgins JPTT J , ed ed. Cochrane Handbook for Systematic Reviews of Interventions. Second. Oxford: The Cochrane Collaboration and John Wiley & Sons Ltd, 2019."},{"key":"2025121408532386000_12.6.e061808.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2025121408532386000_12.6.e061808.26","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.200077"},{"key":"2025121408532386000_12.6.e061808.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i2089"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-061808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:53:37Z","timestamp":1765731217000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-061808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,28]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1136\/bmjopen-2022-061808"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-061808","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}